U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT06960954) titled 'PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma' on April 29.
Brief Summary: The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients.
Researchers will compare PIVKA-II serum levels in HCC patients with PVTT and without PVTT.
Participants will undergo history-taking, clinical examination, laboratory investigations, PIVKA-II serum level, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging,...